AI company Baidu.com, Inc. (BIDU) and French drug major Sanofi (SNYNF,SNY) have entered into an agreement to integrate Baidu's messenger ribonucleic acid (mRNA) design optimization platform, LinearDesign, into Sanofi's product design pipeline.
Under the agreement, Sanofi will leverage the LinearDesign platform to contribute to the optimization of mRNA sequences for human therapeutic and preventive uses.
This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs in real-world pharmaceutical practice beyond Covid-19.
LinearDesign is a novel algorithm developed by Baidu researchers in 2020 specifically for mRNA sequence design. Experiments both in vitro and in vivo have demonstrated the effectiveness of LinearDesign in improving the stability and immunogenicity of Spike protein-encoding mRNA.
The LinearDesign program is part of Baidu's ongoing effort to develop innovative computational biology technology aiming to accelerate novel drug discovery.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.